The DAPA ACT HF-TIMI 68 study is a clinical trial investigating the effect of dapagliflozin on patients hospitalized with acute heart failure. This trial involves patients who have been stabilized during their hospital stay and compares the outcomes of those treated with dapagliflozin versus a placebo. The main goal is to determine if starting dapagliflozin in the hospital can reduce the risk of cardiovascular death or worsening heart failure after discharge.